• BridgeForward Software (Middleton, Massachusetts) reported the general availability of Physician Integrator, an integration solution designed specifically for physician practice integration. The company says that Physician Integrator is an interoperability solution that provides connectivity between a physician's electronic medical record, practice management system or GP system and virtually any other system that requires connectivity including healthcare information exchanges; regional health information organizations; hospital information systems; patient accounting systems; and departmental systems (lab, radiology, pathology, billing, scheduling, dictation, etc.).

• Healthvision (Dallas) said that Sandlot, a subsidiary of North Texas Specialty Physicians (Fort Worth, Texas), is now officially live with the company's Health Information Exchange (HIE) and integrated Electronic Medical Record (EMR) platform, currently serving hospitals, doctors, and other healthcare providers in the Tarrant County area. Cloverleaf Interface Engine, Clinical Portal and Exchange, and Healthvision's Identity Services, which leverages Initiate Master Data Service, play an essential role in this solution by allowing the exchange to create a complete picture of a patients' health record viewable by a physician via a secure Internet connection. Healthvision says that this solution, integrated with Allscripts and NextGen Healthcare EMR systems, allows physicians to make more accurate decisions quickly because they are able to view a patient's entire medical history in one location with one simple request. Where traditionally, the physicians would have to make individual requests to various health care providers visited by the patient, Sandlot aggregates this information and through the use of Healthvision technology, presents a consolidated view to the physician.

• Vitrolife (Göteborg, Sweden) said it has received FDA clearance for its new needle for the collection of human oocytes, Swemed Sense, which reduces the risk of tissue damage and pain. Swemed Sense combines the properties of Vitrolife's previous needles with a new way of designing the front part and tip, so that the patient will experience less discomfort and so that the risk of bleeding is reduced. The Swemed Sense oocyte aspiration needle is designed with a thinner front part and tip so as to minimize tissue damage, bleeding and pain. However, the rear part of the needle has a larger diameter. This makes the needle stable and therefore does not reduce the handling ability. Furthermore, the procedure is just as fast as when a thicker needle is used, which is not the case with uniformly thin needles. The company said patent applications have been submitted for Swemed Sense in all major markets.

• Xenomics (Monmouth Junction, New Jersey) said that it will begin offering a gender prediction test as a service to expectant mothers who are interested in learning the gender of their baby as early as the seventh week of their pregnancy. The Xenomics test is based on the detection of male-specific Y chromosome sequences in maternal urine using the company's technology for the analysis of Transrenal DNA. The service is designed and offered solely for an expectant mother's information and does not provide any medical diagnoses or guidance.

No Comments